THE GENOME OF SARS-COV-2, ITS EVOLUTION AND EPIDEMIOLOGY
This event is sponsored by the
University of Duhok, Covid-19 Center for Diagnostic and Research. COVID-19 is a
life-threatening disease caused by the SARS-CoV-2 virus that has become a major
global public health problem. To date, 584,065,952 people around the world have
been infected, causing 6,418,958 deaths. The genomic sequencing of SARS-CoV-2
patients allows tracking of the epidemiology and evolution of the virus to
inform management options and policies. Researchers in different countries are
making efforts to have information under their own conditions and national
level. Given the opportunity to learn from experiences in other countries,
which may lead to new opportunities for collaboration and accelerate research
in this field, we had the opportunity to have a scientific collaboration with
The Scripps Research Institute in the USA. As a result of this collaboration,
we succeeded in sequencing of the SARS-CoV-2 genome from our regional patients,
and over 600 samples from the Kurdistan Region (Duhok) were sequenced and
analyzed.
We are organizing an international
symposium focused on SARS-CoV2 sequencing and sequence data analysis from
people in the Kurdistan Region (Duhok), which may result in a better
understanding of epidemiology and recommendations for managing the pandemic at
local and international levels.
The aim of the COVID-19: Response
Panel Discussion is to provide much-needed information, perspective, and
learning about COVID-19 for the greater Kurdistan community through a panel
discussion from members of the University of Duhok
All researchers, doctors, and academics from different
universities and health sectors are welcome to participate. Undergraduate and
postgraduate students are also encouraged to apply. The participation could be
through one of the following:
Please click here for registration
Available
Certificates:
All
registered participants will be able to receive their certificates based on
their level of engagement:
In order to be considered for publication, please consider the following points:
created with
Website Builder Software .